MARKET OVERVIEW-UNITED STATES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
In the United States, the syndromic multiplex diagnostic market is expected to witness growth at a specific growth rate over the estimated time period. As the U.S. is one of the major countries presents in North America, the countries have witnessed a growing population with different diseases, including infectious diseases, which has fuelled the demand for diagnostic products. Hence, the syndromic multiplex diagnostic has gained major attention in the U.S. market. The rapidly growing population, the prevalence of infectious diseases, and rising cases of COVID-19 have indeed cultivated the demand for the market. Therefore, the market is expected to find ample new growth opportunities over the forecast period.
MARKET DRIVERS
The United States Syndromic Multiplex Diagnostic market is driven by the rise in prevalence and incidence of various infectious diseases like COVID-19, gastroentitis, pneumonia, meningitis etc., which has boosted the requirement for market products to a major extent. Besides, the growing use and demand of syndromic multiplex diagnostics in major and minor regions is the key factor which has uplifted the market during the estimated time period (2022-2028). Similarly, ongoing R&D along with technological advancements in various diagnostic areas, is expected to contribute to healthy growth in the market.
MARKET OPPORTUNITIES
The market is expected to have new opportunities in the United States. The market in the U.S. is vast with the presence of well-known manufacturers as well as advanced healthcare facilities, which has increased the demand for U.S. syndromic multiplex diagnostic market products. Likewise, the increasing cases of COVID-19, respiratory diseases, and infectious diseases has surged the demand for diagnostic products, which has indeed provided ample new growth opportunities for the syndromic multiplex diagnostic market. These factors have provided ample new growth opportunities for the United States market.
MARKET RESTRAINTS
The market has major restraining factors like false positives in the detection of infectious cases as well as maintenance of syndromic multiplex diagnostic devices is expected to act as a hurdler for the market’s growth over the forecast period.
MARKET GROWTH CHALLENGES
The lack of skilled professionals for the use of syndromic multiplex diagnostics in various applications with improper results is anticipated to be one of the major challenges for the market’s growth.
CUMULATIVE GROWTH ANALYSIS
The report provides an in-depth analysis of the United States Syndromic Multiplex Diagnostic market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. The increasing demand for various United States Syndromic Multiplex Diagnostics in various applications has led to the increasing demand for the market and is expected to witness growth at a CAGR from 2022-2028.
UNITED STATES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET BY INFECTIOUS DISEASES
By Infectious Diseases, the market includes key segment of
- Respiratory Infections
- Human Immunodeficiency Virus (HIV)
- Hepatitis B (HBV)
- Hepatitis C (HCV)
- Human Papillomavirus (HPV)
- Chlamydia/Gonorrhea (CTGC)
- Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Vancomycin-Resistant Enterococcus (VRE)
Respiratory Infections have gained majority of market share in 2021 and are expected to witness growth at a positive growth rate over the estimated time period. The segment is driven by various factors such as the rising incidence of TB, COVID-19, influenza and other respiratory diseases. For instance, tuberculosis cases in the U.S. increased by 9.4% in 2021 after falling by about 20% in 2020. The rising incidence of respiratory diseases is anticipated to provide ample new growth opportunities for the market over the forecast period. Likewise, the human immunodeficiency virus (HIV) is expected to have rising demand for syndromic multiplex diagnostic markets in the United States. In HIV, the market products enable healthcare providers to diagnose and treat patients, preventing the spread of diseases. Thus, the syndromic multiplex diagnostic market offers this infectious disease with accurate diagnosis as well as support for management of diseases.
UNITED STATES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET BY TYPE OF SYNDROME
The United States Syndromic Multiplex Diagnostic market has a type of syndrome present which includes
- Respiratory
- Gastrointestinal
- Bloodstream
- Central Nervous System
The respiratory type of syndrome is likely to dominate in type of syndrome segment. In the U.S. the respiratory syndrome is one of the major problems where most of the population suffers from various respiratory diseases like influenza, TB, COVID-19, and other related respiratory diseases. This factor is expected to boost the sales of syndromic multiplex diagnostic products in the market. Besides, gastrointestinal is anticipated to hold the second position in the market, attributing to rising infectious pathogens. Demand for accurate and early detection of gastrointestinal pathogens is vital to starting the appropriate type of therapy. This factor has led to the rising demand for the market over the forecast period.
UNITED STATES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET BY END USER
The United States Syndromic Multiplex Diagnostic market has end user like
- Hospitals
- Diagnostics Laboratories
- Research Institutes
- Others
Hospitals are anticipated to gain the majority of the market share in the United States. In the U.S., along with the rising number of patients in hospitals, the syndromic multiplex diagnostic has also increased the product demand as well as adoption of these diagnostic tools in hospitals. This factor has boosted the requirement for market products in hospitals. Besides, diagnostics laboratories are expected to hold the second position in the market over the estimated time period.
COVID-19 IMPACT ANALYSIS ON UNITED STATES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360-degree analysis of micro and macro-economic factors on the United States Syndromic Multiplex Diagnostic market. In addition, a complete analysis of changes in the United States Syndromic Multiplex Diagnostic market expenditure, economic and international policies on the supply and demand side. The report also studies the impact of the pandemic on global economies, international trade, business investments, GDP, and marketing strategies of key players present in the market. Likewise, the impact of COVID-19 on the United States Syndromic Multiplex Diagnostic market in the initial phase of the has witnessed more or less impact. However, market has witnessed positive growth during the COVID-19 phase. Most hospital, diagnostic centers have witness patient inflow for testing of COVID-19, which has definitely provided positive growth for the market.
COMPETITIVE LANDSCAPE ANALYSIS
The competitive landscape analysis of the United States Syndromic Multiplex Diagnostic market is majorly focused on expanding the growth of the United States market with new product innovation, business expansion, and the increasing presence of a range of manufacturers operating in the United States has led to the growing demand for the market. Besides, the market offers a range of products for different end users to fulfil the requirements of consumers, which is further contributing to healthy growth in the market.
The key players studied in market are
- Luminex Corp
- Applied biocode corporation
- Akonni biosystems, Inc.
- Thermo fisher scientific, Inc.
- Abbott Laboratories
- Becton, Dickinson and Company
- Hologic, Inc.
- GenMark Diagnostics
- Bio-Rad Laboratories
- Cepheid
- Quidel Corporation
- Bosch Healthcare Solution
- BioFire Diagnostics Company
- Qiagen NV
- OpGen, Inc.
- Quantumdx
RECENT DEVELOPMENT:
November 2021: Qiagen NV. has launched and CE-marked of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly identify whether patients have common seasonal respiratory infections or SARS-CoV-2.
July 2020: bioMerieux announced that BIOFIRE Respiratory Panel 2.1 plus (RP2.1 plus) is CE marked. The panel test for 23 pathogens (19 viruses including SARS-CoV-2 and 4 bacteria) responsible for the most frequent respiratory tract infection. It will be commercially available in all countries that recognize CE marking from now on or shortly thereafter.
May 2020: Thermo Fisher Scientific acquired qiagen’s the molecular diagnostics-focused firm. Qiagen’s specialization in molecular diagnostic services will allow thermo fisher to advance its work in precision medicine by increasing its focus on infectious diseases, cancer, and genetic disorders.
